Beyond Personalization for
Precision Oncology
A patient-first approach to optimize core molecular indicators with ctDNA insights
- How can this NGS test benefit my patient?
- Does it apply for early stages or advanced stages?
- How does it help to monitor treatment?
- 01 - Unique Combination
- Uniquely Combining Genomic Profiling & ctDNA-MRD Monitoring
- 02 - Affordable Solution
- Tailored to Each Patient’s Clinical Condition
- Tumor-informed Methodology
- Tumor-naïve Methodology
- 03 - Efficient Solution
- Clinical Application for Early-Stage and Advanced-Stage Cancers
- Clinically Validated Performance of ctDNA-MRD Monitoring
- 04 - Cancer Types & Technical Specification
01
Beyond Personalization
K-TRACKTM next-generation sequencing assay provides critical insights for a patient's genomic profile, allowing precise identification of treatment eligibility
Personalization continues beyond with selected driver mutations for each person's ctDNA profile, making minimal residual diseases (MRD) detection and dynamic monitoring more precise.
ctDNA utility
Besides performing minimal residual diseases (MRD) detection, our unique mutation & hotspot panel also covers dynamic monitoring of ctDNA profiles for patients at metastatic stages or patients without available tumor sample.
Correlation of dynamic ctDNA and tumor progression
02
A patient-first approach
K-TRACKTM streamlines precision oncology through a unified workflow that optimizes costs and preserves critical tissue. We empower proactive management at every step, from therapy selection to surveillance.
To bring the most optimized, cost-efficient NGS test for a patient, K-TRACKTM studies 04 key molecular indicators unique to each patient: - Actionable mutations
- MSI Status
- Germline mutations
- MRD/Dynamic ctDNA
03
ctDNA assay Clinical Validation
K-TRACKTM assay provides longitudinal ctDNA monitoring that showed clinical utility in predicting disease-free survival and early relapse detection in cancer patients. 1,2,3,4,5
1. Front Oncol vol. 12 1069296. 12 Dec. 2022 | 2. Mol Oncol vol. 17,4 (2023): 598-610 | 3. CO Glob Oncol vol.9, Supp_1 (2023): 110-110 | 4. Annals of Oncology 34 (2023): S1624 | 5. APBCS 2024
Performance Data
Evidence of Treatment Effectiveness & Early Recurrence
04
Cancer Types, Technical Specs & Turn-around time
Technical Performance & Turn-around time
| Panel | Cancer Type | Somatic Mutations (Actionable/Resistance) | ctDNA-MRD Monitoring | MSI Status | Germline Mutations | |
|---|---|---|---|---|---|---|
| Hereditary Cancer Risk | Pharmaco genomics | |||||
| Thoracic Cancers | Lung Cancer | |||||
| Mediastinal Cancer | ||||||
| Mesothelioma Cancer | ||||||
| Digestive Cancers | Ampulla of Vater | |||||
| Bladder Cancer | ||||||
| Cholangiocarcinoma | ||||||
| Colorectal Cancer | ||||||
| Esophageal Cancer | ||||||
| Gallbladder Cancer | ||||||
| Gastric Cancer | ||||||
| GIST | ||||||
| Liver Cancer | ||||||
| Pancreatic Cancer | ||||||
| Breast & Gynecological Cancers | Breast Cancer | |||||
| Cervical Cancer | ||||||
| Endometrial Cancer | ||||||
| Fallopian Tube Cancer | ||||||
| Ovarian Cancer | ||||||
| Uterine Cancer | ||||||
| Other | Prostate Cancer | |||||
Applicable to all cancer stages
Applicable to metastatic stage
| Turn-around Time (working days) | K-TRACK | K-TRACK BO |
|---|---|---|
| Actionable/ Resistance mutations | 05 days (1) | 8 days (3) |
| MSI Status | 05 days (1) | 8 days (3) |
| Germline mutations | 08 days (2) | 8 days (3) |
| ctDNA-MRD baseline | 08 days (2) | 8 days (3) |
| ctDNA-MRD follow-up | 08 days (3) | 8 days (3) |
(*) Turn-around time takes effect upon sample arrival at Gene Solutions' regional oncology labs and clears sample quality checks.
